

SCRI Trials and Trial Regimen Updates

The following updates were completed between June 19, 2025 through July 24, 2025. Sarah Cannon Research Institute now manages all SCRI/USOR trials and trial regimens.

For questions about these trials and regimens, please contact SCRiKMEMRedits@McKesson.com.

New Builds Completed

Study Number	Notes for New Build
24267	USOR 24267 LYM 250 Phase 3 Zanubrutinib + Sonrotoclax or Placebo Q28D
24057	USOR 24057 HN 35 Phase 2 Double-Blind Zanzalintinib or Placebo + Pembrolizumab Q21D
MCCR SARC 08	SARC 08 Phase 1 Ziftomenib + Imatinib Q28D - 26AUG2024
MCCR RM 1275	RM 1275 Phase 1 ENV-501 Q21D - v00 17SEP2024
24200	USOR 24200 HN 40 Phase 3 PDS0101 + Pembrolizumab Q21D - v3.0 12NOV2024 USOR 24200 HN 40 Phase 3 Pembrolizumab Q21D - v3.0 12NOV2024
24208	USOR 24208 BRE 449 Phase 2 Part 1 Safety Lead-in Pembrolizumab + HER3-DXd fb Pembrolizumab + Paclitaxel + Carboplatin Q21D USOR 24208 BRE 449 Phase 2 Part 2 Arm A Pembrolizumab + HER3-DXd fb Pembrolizumab + Paclitaxel + Carboplatin Q21D USOR 24208 BRE 449 Phase 2 Part 2 Arm B Pembrolizumab + Paclitaxel + Carboplatin fb Pembrolizumab + HER3-DXd Q21D USOR 24208 BRE 449 Phase 2 Part 2 Arm C Pembrolizumab + Paclitaxel + Carboplatin fb Pembrolizumab + Doxorubicin or Epirubicin + Cyclophosphamide Q21D USOR 24208 BRE 449 Phase 2 Pembrolizumab +/- Capecitabine (Cycle 9+) Q42D USOR 24208 BRE 449 Phase 2 Pembrolizumab +/- Doxorubicin or Epirubicin + Cyclophosphamide (Q2W) Q42D (Cycle 9+) USOR 24208 BRE 449 Phase 2 Pembrolizumab +/- Doxorubicin or Epirubicin + Cyclophosphamide (Q3W) Q42D (Cycle 9+) USOR 24208 BRE 449 Phase 2 Pembrolizumab +/- Olaparib (Cycle 9+) Q42D

Study Number	Notes for New Build
25023	<p>USOR 25023 MM 195 Phase 2 Arm A Consolidation and Maintenance 1 Elranatamab + Daratumumab Q28D (Cycles 1-15) - v3.0 02APR2025</p> <p>USOR 25023 MM 195 Phase 2 Arm A Maintenance 2 Elranatamab Q28D (Cycles 16-27) - v3.0 02APR2025</p> <p>USOR 25023 MM 195 Phase 2 Arm A1 Late Intensification Maintenance Daratumumab + Lenalidomide Q28D (Cycles 16-27) - v3.0 02APR2025</p> <p>USOR 25023 MM 195 Phase 2 Arm B Maintenance 1 Daratumumab + Lenalidomide Q28D (Cycles 1-12) - v3.0 02APR2025</p> <p>USOR 25023 MM 195 Phase 2 Arm B Maintenance 2 Lenalidomide Q28D (Cycles 13-24) - v3.0 02APR2025</p> <p>USOR 25023 MM 195 Phase 2 Arm B1 Late Intensification and Maintenance Elranatamab + Daratumumab Q28D (Cycles 13-27) - v3.0 02APR2025</p> <p>USOR 25023 MM 195 Phase 2 Conditioning + ASCT (Off-site documentation) - v3.0 02APR2025</p>
24006	<p>USOR 24006 LUN 573 Phase 3 Arm 1 Dato-DXd + Rilvegostomig (AZD2936) Q21D - v2.0 07AUG2024</p> <p>USOR 24006 LUN 573 Phase 3 Arm 2 Rilvegostomig (AZD2936) Q21D - v2.0 07AUG2024</p> <p>USOR 24006 LUN 573 Phase 3 Arm 3 Carboplatin + Pemetrexed Q21D - v2.0 07AUG2024</p> <p>USOR 24006 LUN 573 Phase 3 Arm 3 Cisplatin + Etoposide D1-3 Q28D - v2.0 07AUG2024</p> <p>USOR 24006 LUN 573 Phase 3 Arm 3 Cisplatin + Pemetrexed Q21D - v2.0 07AUG2024</p> <p>USOR 24006 LUN 573 Phase 3 Arm 3 Cisplatin D1 + Vinorelbine D1,8 Q21D - v2.0 07AUG2024</p> <p>USOR 24006 LUN 573 Phase 3 Arm 3 Cisplatin D1 + Vinorelbine D1,8,15,22 Q28D - v2.0 07AUG2024</p> <p>USOR 24006 LUN 573 Phase 3 Arm 3 Cisplatin D1,8 + Vinorelbine D1,8,15,22 Q28D - v2.0 07AUG2024</p>
24165	<p>USOR 24165 RM 1187 Phase 1 Singleplex TCR-T Day 1</p> <p>USOR 24165 RM 1187 Phase 1 Singleplex TCR-T Q29D</p> <p>USOR 24165 RM 1187 Phase 1 T-Plex TCR-T Q29D</p> <p>USOR 24165 RM 1187 Regimen A Lymphodepletion Cyclophosphamide + Fludarabine Q7D</p> <p>USOR 24165 RM 1187 Regimen B Lymphodepletion Cyclophosphamide + Fludarabine Q7D</p> <p>USOR 24165 RM 1187 Regimen C Lymphodepletion Cyclophosphamide + Fludarabine Q7D</p>

Study Number	Notes for New Build
23302	USOR 23302 BRE 431 Phase 3 Arm A MK-2870 Q84D - 15NOV2024 USOR 23302 BRE 431 Phase 3 Arm B MK-2870 + Pembrolizumab Q84D - 15NOV2024 USOR 23302 BRE 431 Phase 3 Arm C Capecitabine Q84D - 15NOV2024 USOR 23302 BRE 431 Phase 3 Arm C Liposomal Doxorubicin Q84D - 15NOV2024 USOR 23302 BRE 431 Phase 3 Arm C Nab-Paclitaxel Q84D - 15NOV2024 USOR 23302 BRE 431 Phase 3 Arm C Paclitaxel (80 mg/m ²) Q84D - 15NOV2024 USOR 23302 BRE 431 Phase 3 Arm C Paclitaxel (90 mg/m ²) Q84D - 15NOV2024
24199	USOR 24199 GI 390 Phase 2 Substudy 1 Stage 1 or 2 Telisotuzumab adizutecan + FOLFOX + Bevacizumab Q28D USOR 24199 GI 390 Phase 2 Substudy 1 Stage 2 FOLFOX + Bevacizumab Q28D USOR 24199 GI 390 Phase 2 Substudy 2 Stage 1 or 2 Telisotuzumab adizutecan + Fluorouracil + Leucovorin + Panitumumab Q28D USOR 24199 GI 390 Phase 2 Substudy 2 Stage 2 FOLFOX + Panitumumab Q28D
24217	USOR 24217 MULTI 96 Phase Ib WTX-124 + Pembrolizumab Q42D 04OCT2024 USOR 24217 MULTI 96 Phase Ib WTX-124 Q28D 04OCT2024
24079	USOR 24079 MM 193 Phase 3 (DRd) Daratumumab + Lenalidomide + Dexamethasone Q28D USOR 24079 MM 193 Phase 3 (Tal-DR) Talquetamab + Daratumumab + Lenalidomide + Dexamethasone Q28D USOR 24079 MM 193 Phase 3 (Tec-DR) Teclistamab + Daratumumab + Lenalidomide + Dexamethasone Q28D
24285	USOR 24285 GI 403 Phase 3 Octreotide LAR Q28D - v00 09DEC2024 USOR 24285 GI 403 Phase 3 [177Lu] Lu-DOTA-TATE + Octreotide LAR Q56D - v00 09DEC2024
23041	USOR 23041 MPN 21 Phase 3 Givinostat Q112D v7.0 19NOV2024 USOR 23041 MPN 21 Phase 3 Givinostat Q28D v7.0 19NOV2024 USOR 23041 MPN 21 Phase 3 Hydroxyurea Q28D v7.0 19NOV2024

Updated Reference Information

Study Number	Updated Reference Information	Updated Drug Service Order Information	Updated Regimen Instructions	Other Changes
22067	N/A	N/A	N/A	Updated drug: Admin Prep
22273	N/A	N/A	N/A	Closed Arm
23337	N/A	N/A	N/A	Added Drug, Updated drug admin/prep
24100	Version 4.0, 30April12025	N/A	N/A	Updated Drug, Admin Prep
24112	N/A	N/A	N/A	Updated drug instructions.
24250	N/A	N/A	N/A	Updated drug instructions.
23297	N/A	N/A	N/A	Updated drug, Admin/prep
24171	PA 3, 12 March 2025	N/A	Regimen Comments: Prophylaxis, Observation	Updated drug instructions
24145	PA 6.0, 18 Feb 2025	N/A	N/A	Updated drug instructions, Updated Dose/Form
24026	PM V3; 30 Jan 2025	N/A	N/A	Updated drug instructions
23141	PA 08: 01 April 2025	N/A	Regimen Comments: Prophylaxis	N/A
24070	Memo, 07 April 2025	N/A	N/A	Updated drug dose, updated drug name
23129	Version 5.0, 29APR2025	N/A	N/A	Updated drug instructions

Study Number	Updated Reference Information	Updated Drug Service Order Information	Updated Regimen Instructions	Other Changes
24224	N/A	N/A	N/A	Updated drug: Admin/prep
24288	V2.1, 09 April 2025	N/A	N/A	Updated drug: Admin/prep
23166	PA V10.0, 12 MAY 2025	N/A	N/A	Reference change
22201	N/A	N/A	N/A	Added Drug
24089	PA v5.0, 28 JAN 2025	N/A	N/A	Updated drug instructions
23340	PA V3.0, 29 MAY 2025	N/A	Regimen Comments: Administration	Updated drug instructions
24030	PA2; 11 DEC 2024	N/A	Regimen Comments: Administration	N/A
23309	Amendment 7, 30APR2025	N/A	Regiment comments; prophylaxis	Updated drug instructions
23084	PA v5.0: 28 Feb 2025	N/A	Regimen comments: administration, prophylaxis	Updated drug instructions, admin prep, premedication